Enanta制药是一家临床阶段生物技术企业,专注于研发针对乙型肝炎病毒、呼吸道合胞病毒、新冠病毒等传染性疾病的创新抗病毒疗法,与全球制药伙伴合作推进小分子候选药物管线,满足未被覆盖的临床需求。
CTMX
CytomX Therapeutics, Inc.
营收
$18.7M
净利润
$-154.0K
NAMS
凯特制药
$19.1M
$-17.4M
CYTK
CYTOKINETICS INC
$17.8M
$-183.0M
UBFO
UNITED SECURITY BANCSHARES
$13.5M
$3.4M
KURA
藏寿司
$17.3M
N/A
AGIO
AGIOS PHARMACEUTICALS, INC.
$20.0M
$-108.0M
CBK
Commercial Bancgroup, Inc.
$23.1M
$9.5M
TRDA
Entrada Therapeutics, Inc.
$20.6M
$-17.3M